Lyra Therapeutics Inc (LYRA) - מקדם חוב לטווח ארוך להון

The long-term financial leverage ratio demonstrates the current balance sheet stability of Lyra Therapeutics, Inc. (LYRA), where the parameter value equals 0.00. Robotic assembly of micro-components guarantees device quality; however, failures in late-stage sinusitis tests triggered an acute liquidity crisis. Business stability relies on XTreo, a drug delivery system that creates an exclusive dependence of clinics on implant supplies.

Low debt leverage traditionally serves as a sign of an issuer's financial stability. This ratio correlates liabilities with a maturity of more than one year to total capital, measuring the business's degree of dependence on external borrowings. By analyzing the trajectory of the long-term debt-to-equity ratio, an investor assesses the actual financing structure. For Lyra Therapeutics, Inc. (LYRA), this indicator is critical due to the depletion of resources following unsuccessful tests. Debt control currently determines the company's ability to survive amidst restructuring.